KPTI vs MKC · rev $68.5M vs P/E 8.4, rev $3.81B
Karyopharm Therapeutics Inc (KPTI) versus McCormick & Company Incorporated (MKC) — a side-by-side from cached financials, not a winner call.
Karyopharm Therapeutics Inc (KPTI) is a biotechnology company listed on US.
McCormick & Company Incorporated (MKC) is a packaged foods company listed on US.
Latest reported KPTI revenue for 2026-06-30 was $68.5M. Net income was -$89.4M. Revenue was up 95.3% from 2026-03-31 to 2026-06-30. KPTI currently screens at market cap $205.6M.
Latest reported MKC revenue for 2026-05-31 was $3.81B. Net income was $1.17B. MKC currently screens at market cap $13.56B and trailing P/E 8.4.
KPTI currently screens at market cap $205.6M. MKC currently screens at market cap $13.56B and trailing P/E 8.4.
Not investment advice. Open the KPTI and MKC stock pages for the full models.
Not investment advice.